Preventing hepatitis B reactivation due to immunosuppressive drug treatments

JAMA. 2015 Apr 28;313(16):1617-8. doi: 10.1001/jama.2015.2571.

Authors

Robert P Perrillo¹, Paul Martin², Anna S Lok³

Affiliations

¹ Hepatology Division, Baylor University Medical Center, Dallas, Texas.
² Division of Hepatology, University of Miami, Miami, Florida.
³ Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor.

PMID: 25790287
DOI: 10.1001/jama.2015.2571

No abstract available

MeSH terms

Hepatitis B / immunology
Hepatitis B / prevention & control*
Hepatitis B virus / physiology*
Humans
Immunosuppressive Agents / adverse effects*
Immunosuppressive Agents / therapeutic use
Practice Guidelines as Topic
Risk

Substances

Immunosuppressive Agents